Literature DB >> 3929859

Tissue plasminogen activator release in vivo in response to vasoactive agents.

D Smith, M Gilbert, W G Owen.   

Abstract

Release of tissue plasminogen activator into the circulation of rats in response to intravascular injections of vasoactive agents is studied by using a sensitive and specific clot lysis assay. Intra-arterial bradykinin elicits a rapid and transient rise in circulating plasminogen activator, which is maximum within one minute and is cleared within four to eight minutes. The plasminogen activator is fibrin dependent and is neutralized by an antiserum to human tissue-type plasminogen activator. Bradykinin is 1,000-fold more potent than the other agonists tested, which include histamine, norepinephrine, epinephrine, eledoisin-related peptide, arginine-vasopressin, lysine-vasopressin, desmopressin acetate, carbachol, and acetylcholine. Potency of bradykinin is related to its amino acid sequence. Sequential infusions of bradykinin produce a tachyphylactoid response that could be overcome by increasing the dose of the sequential bradykinin challenge. It is concluded that the characteristics of the responses to bradykinin and other agents in vivo differ significantly from those observed in isolated tissue preparations.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3929859

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

Review 1.  Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications.

Authors:  I B Wilkinson; D J Webb
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

Review 2.  The importance of the endothelium in atherothrombosis and coronary stenting.

Authors:  Fumiyuki Otsuka; Aloke V Finn; Saami K Yazdani; Masataka Nakano; Frank D Kolodgie; Renu Virmani
Journal:  Nat Rev Cardiol       Date:  2012-05-22       Impact factor: 32.419

Review 3.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

4.  Endothelial retention and phenotype on carbonized cardiovascular implant surfaces.

Authors:  Christopher M Frendl; Scott M Tucker; Nadeem A Khan; Mandy B Esch; Shrinidhi Kanduru; Thong M Cao; Andrés J García; Michael R King; Jonathan T Butcher
Journal:  Biomaterials       Date:  2014-06-20       Impact factor: 12.479

5.  Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor.

Authors:  R W Colman; R A Pixley; S Najamunnisa; W Yan; J Wang; A Mazar; K R McCrae
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

6.  In vivo bradykinin B2 receptor activation reduces renal fibrosis.

Authors:  Joost P Schanstra; Eric Neau; Pascale Drogoz; Miguel A Arevalo Gomez; José Miguel Lopez Novoa; Denis Calise; Christiane Pecher; Michael Bader; Jean-Pierre Girolami; Jean-Loup Bascands
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 7.  [The renin-angiotensin system in cardiovascular diseases].

Authors:  C Unterberg; H Kreuzer; A B Buchwald
Journal:  Med Klin (Munich)       Date:  1998-07-15

Review 8.  Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection.

Authors:  Domenico Galzerano; Cristina Capogrosso; Sara Di Michele; Emanuele Bobbio; Paola Paparello; Carlo Gaudio
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

9.  Histamine-induced vasodilatation in the human forearm vasculature.

Authors:  Euan A Sandilands; Jane Crowe; Hayley Cuthbert; Paul J Jenkins; Neil R Johnston; Michael Eddleston; D Nicholas Bateman; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

10.  Interaction study between nifedipine and recombinant tissue-type plasminogen activator in healthy subjects.

Authors:  A De Boer; C Kluft; F J Kasper; J M Kroon; H C Schoemaker; D D Breimer; P A Soons; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.